Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CAMP4 THERAPEUTICS CORPORATION (CAMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: CAMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.4
1 Year Target Price $10.4
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.96% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.82M USD | Price to earnings Ratio - | 1Y Target Price 10.4 |
Price to earnings Ratio - | 1Y Target Price 10.4 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 1.30 - 12.26 | Updated Date 10/30/2025 |
52 Weeks Range 1.30 - 12.26 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -870.27% |
Management Effectiveness
Return on Assets (TTM) -82.62% | Return on Equity (TTM) -188.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28151997 | Price to Sales(TTM) 25.88 |
Enterprise Value 28151997 | Price to Sales(TTM) 25.88 | ||
Enterprise Value to Revenue 9.36 | Enterprise Value to EBITDA - | Shares Outstanding 20161073 | Shares Floating 9803322 |
Shares Outstanding 20161073 | Shares Floating 9803322 | ||
Percent Insiders 41.75 | Percent Institutions 112.35 |
Upturn AI SWOT
CAMP4 THERAPEUTICS CORPORATION
Company Overview
History and Background
CAMP4 Therapeutics Corp. was founded in 2016 to develop RNA-based therapies targeting gene expression. It leverages its proprietary platform to upregulate gene expression to treat diseases.
Core Business Areas
- RNA Activating Therapeutics: CAMP4's core business is developing RNA activating therapeutics to treat genetic diseases by upregulating gene expression at the transcriptional level.
Leadership and Structure
The company is led by a management team with expertise in RNA therapeutics and drug development. Specific details on the organizational structure are generally available in their SEC filings.
Top Products and Market Share
Key Offerings
- CAG-001: CAG-001 is Camp4's lead therapeutic candidate, intended to treat Rett syndrome by selectively upregulating the expression of the MECP2 protein. Clinical trials are underway and no revenue has been generated yet. Competitors are developing similar therapies using gene therapy approaches, such as Taysha Gene Therapies (TSHA).
Market Dynamics
Industry Overview
The RNA therapeutics market is rapidly growing, driven by advancements in RNA biology and delivery technologies. It addresses a wide range of diseases, including genetic disorders, cancer, and infectious diseases.
Positioning
CAMP4 is positioned as a leader in developing RNA activating therapeutics, differentiating itself by focusing on upregulating gene expression as opposed to silencing it.
Total Addressable Market (TAM)
The TAM for RNA therapeutics is estimated to be in the billions of dollars and continually growing. CAMP4 is targeting specific genetic diseases, which represent a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary RNA activating technology platform
- Strong intellectual property position
- Experienced management team
- Focus on a novel therapeutic approach
Weaknesses
- Early stage of development, dependent on clinical trial success
- High risk of failure associated with drug development
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on proprietary technology platform, potential limitations
Opportunities
- Expansion of pipeline to address additional genetic diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial data leading to regulatory approval
- Advancements in RNA delivery technologies
Threats
- Clinical trial failures
- Competition from other RNA therapeutics companies
- Changes in regulatory landscape
- Patent disputes
Competitors and Market Share
Key Competitors
- ALNY
- IONS
- MRNA
Competitive Landscape
CAMP4's competitive advantage lies in its RNA activating technology. It faces competition from established RNA therapeutics companies with larger pipelines and resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and expansion of the pipeline.
Future Projections: Future growth projections depend on successful clinical trials and potential regulatory approvals. Analyst estimates will be available as the company matures.
Recent Initiatives: Recent initiatives include advancing CAG-001 into clinical trials and expanding the research pipeline.
Summary
CAMP4 Therapeutics is an early-stage company focused on RNA activating therapeutics. Its proprietary technology presents a promising approach for treating genetic diseases. The company's success depends on positive clinical trial results and securing partnerships, while competition and regulatory hurdles present challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- CAMP4 Therapeutics Corp. Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CAMP4 THERAPEUTICS CORPORATION
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2024-10-11 | CEO, President & Director Mr. Joshua Mandel-Brehm | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.camp4tx.com |
Full time employees 55 | Website https://www.camp4tx.com | ||
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.